As an affiliate of GobyMeds, I earn a commission from qualifying purchases. Black Friday code BF26GP: $50 off a new patient's first order, not refills; type it at checkout. Ends Dec 2 at 11:59 p.m. Pacific.

Compounded Semaglutide After the Shortage: FDA Enforcement and Switch Options

FDA resolved the semaglutide shortage on February 21, 2025. Temporary shortage-based enforcement discretion ended after an April 24 court decision for 503A pharmacies and on May 22 for 503B facilities.

This guide separates those dates from FDA's pending 503B bulk-list proposal and compares paths to discuss with a prescriber.

June 19, 202613 min read

By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.

Summarize this article with

Editorial photograph illustrating the FDA compounded semaglutide enforcement crackdown

FDA resolved the semaglutide shortage on February 21, 2025. Its shortage-related enforcement discretion for 503A semaglutide injection compounding ended after the April 24, 2025 court decision; the 503B period ran through May 22, 2025.

FDA's dated policy log records both transitions.

Those dates ended a broad shortage pathway; they did not create a one-sentence federal ban on every patient-specific compounded prescription.

A particular preparation must satisfy the applicable section 503A or 503B and state-law conditions, including restrictions on products that are essentially copies of commercially available drugs.

March 2026 Marketing Update

On March 3, 2026, FDA announced warning letters to 30 telehealth companies over marketing that presented compounded GLP-1 products as approved, generic, identical, or clinically equivalent to approved brands.

That agency-wide announcement is broader than our non-exhaustive provider tracker and does not mean every letter alleged an unsafe medication.

Separately, FDA's April 30 proposal would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list.

The comment period closed July 30, 2026; a closed comment period does not make a proposed rule final.

See the FDA's concerns about unapproved GLP-1 drugs and our 503B proposal guide.

One program we track, MEDVi, received letter 721455 on February 20, 2026, over marketing claims rather than any finding about the medication itself; the review carries its price and service record, and the safety checker the letter.

Quick answer: paths to discuss with your prescriber:

This guide covers the sourced FDA timeline, product-safety concerns reported by the agency, and public records you can review in our warning and transparency checker.

The checker is not an exhaustive FDA database and cannot verify a provider's compliance or certify a medication as safe. For the legal framework, see the brand vs compounded guide.

Check the rules before you choose a program

Ask any program which medication you'd get, which pharmacy makes it and who writes the prescription. The FDA alerts page shows what has changed.

Read FDA alerts and compounding updates →

What Happened: The FDA Crackdown Timeline

The legal status of compounded GLP-1 medications changed significantly over the past 18 months. Here is the timeline of how it unfolded:

What Happened: The FDA Crackdown Timeline
DateEvent
Feb 21, 2025FDA determined the semaglutide injection shortage was resolved
Apr 24, 2025A federal district court decided a preliminary-injunction request, ending FDA's temporary enforcement-discretion period for state-licensed 503A pharmacies making shortage-based copies (FDA had extended it from April 22 to the later of that date or the ruling)
May 22, 2025FDA's temporary enforcement-discretion period ended for 503B outsourcing facilities making shortage-based copies
May, Sep 2025FDA issued warning letters to compounding pharmacies that continued operations, including JulyMD (September 2025)
Late 2025Court challenges from pharmacy groups temporarily complicated enforcement but did not overturn FDA authority
Mar 3, 2026FDA announced 30 warning letters to telehealth companies over marketing of compounded GLP-1 products. The announcement addressed promotional claims; it did not state that every cited medication was unsafe.
Apr 30, 2026FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period, extended under Docket FDA-2018-N-3240, closed July 30, 2026. The proposal is not a final rule.
Feb 6, 2026 (delayed public disclosure Jun 2026)HHS General Counsel referred Hims & Hers Health to the Department of Justice for compounding violations, the most significant telehealth enforcement escalation to date.
Jul 30, 2026 (extended from Jun 29)Public comments closed on FDA's 503B bulk-list proposal. Closing comments is a procedural milestone, not finalization of the proposal.
What the April 30, 2026 Proposal Means

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list when they are compounded from bulk substances under that pathway.

The proposal must be distinguished from the separate drug-shortage pathway and from patient-specific 503A rules.

Comments closed July 30, 2026, but FDA has not set a finalization date in the cited notice; do not treat the proposal as current final law.

The core change is narrower: shortage status had supported temporary enforcement discretion for certain copies under FDA policy. Once FDA resolved the semaglutide shortage, that shortage route and its transition periods ended.

Other section 503A or 503B conditions still require a fact-specific analysis; the shortage decision alone does not answer every compounding scenario.

The answer depends on the specific prescription, pharmacy, substance, and applicable federal and state rules.

Section 503A can apply to patient-specific prescriptions, but it has multiple conditions, including limits on products that are essentially copies of commercially available drugs.

A prescriber-documented determination that a compounded version produces a significant difference for an identified patient can be relevant; it is not an automatic exemption from every other requirement.

  • •Patient-specific prescription, Section 503A generally requires compounding for an identified individual patient under a valid prescription or the statute's limited anticipatory-compounding conditions.
  • •Essentially-a-copy analysis, When a commercially available drug exists, the prescriber should document any patient-specific significant difference rather than relying on a generic claim such as lower price or convenience.
  • •All other conditions, Ingredient eligibility, pharmacy practice, labeling, state law, and other statutory conditions still apply. Section 503B uses a separate framework and FDA registration does not approve a compounded product.
Important

Do not infer compliance from a provider's claim that a product is customized, from a low advertised price, or from a pharmacy appearing in a registry.

Ask the prescriber and pharmacist to explain the patient-specific rationale and the legal pathway they rely on. For legal advice about a particular prescription or facility, consult qualified counsel or the relevant regulator.

FDA's April 30, 2026 proposal concerns the 503B bulk drug substances list and is not yet a final rule.

Track sourced regulatory updates at our safety center or read the dedicated 503B proposal guide.

Your 4 Options as a Former Compounded Semaglutide Patient

If you were relying on compounded semaglutide, you have four realistic paths forward. Here is a quick comparison before we detail each:

Your 4 Options as a Former Compounded Semaglutide Patient
OptionMonthly CostAvailabilityBest For
Compounded tirzepatide$149 to $299/mo advertisedTirzepatide shortage resolved; any compounding requires case-specific reviewPatients whose prescriber identifies an appropriate formulation and lawful pathway
Brand Wegovy + savings card$0 to $650/moWidely available with insurancePatients with commercial insurance covering GLP-1
NovoCare patient assistance$0Income-based eligibilityPatients at ≤400% federal poverty level
Foundayo (oral GLP-1 pill)$149-$349/mo (dose/refill terms)Prescription requiredPatients who prefer pills over injections

Option 1: Discuss Compounded Tirzepatide With Your Prescriber

FDA resolved the tirzepatide shortage on October 2, 2024, and shortage-based enforcement discretion ended in early 2025.

Services still advertise compounded tirzepatide, but availability through a licensed pharmacy does not establish that a particular preparation meets every 503A or 503B and state-law condition.

The SURMOUNT-1 trial studied Eli Lilly's branded tirzepatide product; its weight-loss results do not establish the effectiveness of a compounded formulation.

Compare advertised compounded tirzepatide plans by formulation, dose and recurring total, not just a first-month offer. Confirm the medication, consultation, shipping and any required fees before paying:

Option 1: Discuss Compounded Tirzepatide With Your Prescriber
ProviderMonthly CostOur RatingKey Strength
EverPrime compounded tirzepatide plansConfirm total commitment and billing schedule9.4/10Plan-dependent terms; prescription requires clinician review
Shed$299/mo7.9/102-3 day shipping, clean app
Sprout Health (2025 FDA warning for misleading compounded-drug marketing)$199 every 4 weeks7.8/10, active alerts: FDA warning, delivery complaintsCompounded tirzepatide shortest plan; annual option is $1,788 upfront ($149/month equivalent). Review reputation evidence
Direct Meds (2025 FDA warning for misleading compounded-drug marketing)$399/mo7.5/10, active alert: FDA warningPublished tirzepatide injection tier; check whether your order renews and the cancellation cutoff in the terms

For a full comparison, see our compounded tirzepatide guide and cheapest tirzepatide rankings.

Before paying any provider, ask for the dispensing pharmacy's legal name, check the applicable state license or 503B registration and inspection record, and confirm the exact formulation and concentration.

We do not certify 503A/503B compliance.

Key context

The tirzepatide shortage was already resolved in October 2024. Do not prepay or stockpile based on an urgency claim that the shortage is still active.

Regulatory status and provider terms can change; review current primary sources and our safety center before each renewal.

Option 2: Brand-Name Wegovy with Manufacturer Savings

Brand Wegovy (semaglutide 2.4mg weekly injection) is FDA-approved and widely available through telehealth providers and traditional pharmacies.

The list price is approximately $1,349/month, but several programs significantly reduce that cost:

  • •Wegovy Savings Card, If you have commercial insurance that covers Wegovy, the Novo Nordisk savings card reduces your copay to as low as $0/month for the first month and up to $500/month savings. Cannot be used with Medicare, Medicaid, or any government insurance.
  • •NovoCare Patient Assistance Program, Free Wegovy for patients at or below 400% of the federal poverty level (approximately $60,000/year for a single person in 2026). Apply at novonordisk-us.com. Income and residency verification required.
  • •GoodRx coupons, Reduce out-of-pocket Wegovy cost to $800 to $950/month without insurance. Not ideal long-term, but useful as a bridge while pursuing insurance coverage.
  • •Telehealth providers with insurance verification, Several providers in our rankings will verify your insurance coverage and help with prior authorization appeals if you are denied.

If you had insurance coverage for compounded semaglutide through a telehealth provider, note that coverage for brand Wegovy often requires a separate prior authorization.

Our insurance lookup tool can help you check your plan's GLP-1 coverage status.

Option 3: Foundayo (Oral Orforglipron), The Pill Alternative

Foundayo (orforglipron) is a newly FDA-approved oral GLP-1 receptor agonist that was approved for chronic weight management in early 2026.

Unlike injectable semaglutide or tirzepatide, it is taken once daily as a pill, no compounding, no injections, standard pharmacy dispensing.

  • •Phase 3 trial results: In ATTAIN-1, the highest trial dose (36 mg) produced an 11.2% average weight reduction at week 72, against 2.1% on placebo. These results describe adults with obesity without diabetes under the treatment-regimen estimand, not a direct comparison with injectable semaglutide or tirzepatide. The trial strength refers to a study formulation, not a commercial tablet dosing instruction.
  • •Cost: $649/month list price; LillyDirect self-pay runs $149 to $349/month depending on dose and refill timing (checked September 20, 2026)
  • •Key advantage: Oral route, no cold storage required, available at standard retail pharmacies
  • •Evidence limit: Results from separate trials do not establish a head-to-head efficacy ranking against injections.

Read the full analysis in our Foundayo price and dose page and our Foundayo vs Wegovy pill comparison.

The ATTAIN-1 and Wegovy 25 mg weight-management results come from separate placebo-controlled trials; those averages are not a head-to-head comparison or a prediction of your result.

Option 4: Appeal Your Insurance Denial

If your insurer previously denied GLP-1 coverage, that has changed. As of 2026, most major commercial insurers cover at least one GLP-1 medication for obesity when medical necessity is documented. A strong appeal should include:

  • •BMI documentation, A BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, obstructive sleep apnea, cardiovascular disease)
  • •Prior treatment documentation, Evidence of failed attempts with at least one other weight management approach
  • •Letter of medical necessity, From your prescribing provider, ideally a physician or NP, documenting clinical need
  • •Specific drug requested, Appeal for the specific covered GLP-1 on your formulary; use your insurer's preferred drug if one is listed

Use our insurance lookup tool to check GLP-1 coverage policies by major insurer, or our eligibility checker to see if you meet the criteria insurers typically require.

How to Choose Between Your Options

Your best path depends primarily on your insurance situation and weight loss goals:

How to Choose Between Your Options
Your SituationBest Option
No insurance, want the lowest costGala lists compounded tirzepatide from $99/mo equivalent on an annual plan billed once a year; compare the full payment and other plans at /cheapest-tirzepatide
Had good results on compounded semaglutideAsk the prescriber to reassess the exact product; branded-trial efficacy cannot be transferred to compounded options
Commercial insurance covering GLP-1sBrand Wegovy or Zepbound with savings card
Income ≤400% federal poverty levelNovoCare patient assistance (free Wegovy)
Hate injections, prefer pillsFoundayo (orforglipron) $149-$349/mo by dose/refill timing
Medicare or Medicaid patientCheck the exact benefit: Medicare Bridge has separate eligibility; Medicaid rules depend on the state and plan
Previously denied by insuranceAppeal with medical necessity letter; use our insurance tool

Not sure which provider to use? Take our 7-question match quiz, it factors in your budget, insurance status, injection preference, and health goals to recommend the best provider for your situation.

Or see all options ranked by price on our cheapest GLP-1 medication guide, or use the cost calculator to see a side-by-side price comparison.

What This Means for Semaglutide vs. Tirzepatide

Post-shortage enforcement has led some telehealth services to promote tirzepatide instead. That commercial shift should not be mistaken for an efficacy conclusion.

Head-to-head and pivotal trials compare specific FDA-approved branded products; they do not establish outcomes for compounded formulations.

Our semaglutide vs tirzepatide comparison keeps the branded clinical evidence separate from compounded price listings.

What This Means for Semaglutide vs. Tirzepatide
FactorCompounded Semaglutide (was)Compounded Tirzepatide (now)
Regulatory contextSemaglutide shortage resolved Feb 2025; case-specific 503A/503B analysisTirzepatide shortage resolved Oct 2024; case-specific 503A/503B analysis
Clinical weight lossNot established for a compounded product; STEP 1 studied branded WegovyNot established for a compounded product; SURMOUNT-1 studied branded tirzepatide
Lowest monthly cost$99/mo (was)$149/mo
MechanismGLP-1 agonist onlyDual GLP-1 + GIP agonist
DosingWeekly injectionWeekly injection

Advertised compounded prices differ, but there is no defensible compounded-product 'weight loss ceiling' to divide into those prices. Individual reports do not substitute for product-specific trials.

If a prescriber considers a patient-specific compounded formulation, Willow advertises its GLP-1 program at $299/mo; verify the exact drug, ongoing total, dispensing pharmacy, and legal basis before enrolling.

See our brand vs compounded GLP-1 guide for the regulatory framework.

Frequently Asked Questions

Is compounded semaglutide completely illegal in 2026?

Is compounded semaglutide completely illegal in 2026?

No blanket statement covers every preparation. FDA resolved the semaglutide shortage and ended temporary shortage-based enforcement discretion in 2025.

A patient-specific 503A prescription or a 503B preparation must still satisfy all applicable federal and state conditions; FDA's 2026 503B bulk-list action remains a proposal, not a final universal ban.

Can I still get compounded semaglutide from my telehealth provider?

Can I still get compounded semaglutide from my telehealth provider?

Some telehealth providers still advertise compounded semaglutide. An advertisement does not establish that a particular prescription or batch meets section 503A or 503B and state-law conditions.

Ask for the dispensing pharmacy, exact formulation and concentration, patient-specific rationale, and current license or registration record before paying.

How do I know if tirzepatide is right for me after semaglutide?

How do I know if tirzepatide is right for me after semaglutide?

A prior response to one compounded formulation does not predict your response to another.

Tirzepatide and semaglutide have different receptor activity, labeled dosing, contraindications, and evidence bases, while compounded products add formulation and concentration uncertainty.

A prescriber should reassess your history and the exact proposed product; our eligibility checker is educational and cannot make that clinical decision.

Will compounded tirzepatide also be banned?

Will compounded tirzepatide also be banned?

No final FDA action cited here creates a simple future 'ban' answer. Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025.

FDA's April 30, 2026 proposal would affect the 503B bulk-list pathway if finalized, but comments closing did not finalize it.

FDA's March 3, 2026 announcement of 30 telehealth marketing letters addressed promotional claims, not a blanket product-safety finding. Check our safety center for sourced updates.

What happens to patients on Medicare who can't get compounded semaglutide?

What happens to patients on Medicare who can't get compounded semaglutide?

Medicare's basic Part D benefit excludes weight-loss-only use, while qualifying non-weight-management indications can follow plan-specific coverage rules.

The separate Bridge began July 1, 2026 and includes certain branded formulations for eligible patients, not compounded semaglutide.

Medicaid is a different program with state and plan rules. Medicare's covered products and our coverage guide explain the next steps.

Sources

Some links pay us a commission. That never changes a score or a ranking. How we work

Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.

Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.

Medicare & GLP-1

Medicare GLP-1 Coverage Guide

On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.

Read the Medicare guide →
Independent Clinical Perspective

What the doctors say

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
Jacqueline M. Stephens, PhD, FTOS, President, The Obesity Society
The Obesity Society
Official Obesity Society statement on compounded GLP-1 medications.
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
Marc-Andre Cornier, MD, endocrinologist; immediate past president of The Obesity Society
Medical University of South Carolina
On why some online/telehealth GLP-1 programs fall short of a proper clinical standard of care.
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs, but compounders should not try to compound drugs in a way that circumvents FDA's approval process.”
Marty Makary, MD, MPH, FDA Commissioner
U.S. Food and Drug Administration
Announcing 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products.
FDA.gov ↗ · Mar 2026

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.

Featured Partners

Affiliate partners we feature. We may earn a commission.

Embody

Embody illustration of a compounded semaglutide injection vial
from $79/mo·Compounded

Compounded semaglutide injection, month to month; lowest plan price, may need a longer plan

Collective

Semaglutide options·Compounded

Gala

Gala provider illustration of compounded semaglutide injection vial
from $69/mo, billed yearly·Brand & Compounded

Compounded Semaglutide (yearly plan); annual plan, billed once a year; final price depends on state, dose and plan

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.